Sissetulev kiriAvalik
Euroopa farmakopöa töökava asjus
Ravimiamet · 29. aprill 2025
- Viit
- REP-1/2187-1
- Registreeritud
- 29. aprill 2025
- Dokumendi liik
- Sissetulev kiri
- Adressaat
- European Directorate for the Quality of Medicines & HealthCare
- Saabumis/saatmisviis
- e-post
- Funktsioon
- REP Euroopa Farmakopöaga seotud asjaajamine
- Sari
- REP-1 Euroopa Farmakopöa alane kirjavahetus
- Toimik
- REP-1/2025
- Vastutaja
- Signe Leito (RA, Peadirektori asetäitja valdkond, Labor)
Sisu (failidest)
Signe Leito
Saatja: [email protected]
Saatmisaeg: reede, 25. aprill 2025 13:34
Adressaat: Signe Leito
Teema: Survey: proposed addition of a new monograph Dapagliflozin to the work programme of Group 10D: EDQM-2025-01796-mail
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada.
Please make sure to include in any reply our mail reference: EDQM-2025-01796-mail
****************************************************************************
For the attention of NPAs
Copy: Presidium
Dear Colleagues,
Please find below the link to a survey being carried out concerning the proposed addition of the
monograph on Dapagliflozin to the work programme of Group 10D.
In order to have access to the survey, please copy and paste this link into your Internet browser:
https://survey.edqm.eu/index.php?r=survey/index&sid=165942&lang=en
Deadline for replies: 27 May 2025.
Thank you.
With kind regards
On behalf of Dr Mathilde Capderou
___
Villy Nikolova
Administrative Support Assistant
European Pharmacopoeia Department
EDQM
Council of Europe
Tel.: +33 (0)3 90 21 64 63 / Fax: +33
(0)3 88 41 27 71
https://www.edqm.eu / https://www.edqm.eu/store
1
Stay connected with the EDQM
****************************************************************************
Please make sure to include in any reply our mail reference: EDQM-2025-01796-mail
2